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STEM CELL TRANSPLANTATION AND ALLOGENEIC BONE
MARROW TRANSPLANTATION IN ADULT HEMATOLOGIC
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This retrospective study compared the outcomes in 32 adult patients with hematologic diseases (acute myeloid
leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, severe aplastic
anemia) who received allogeneic bone marrow transplantation (BMT, n = 14; median age, 28 years) or allogeneic
peripheral blood stem cell transplantation (PBSCT, n = 18; median age, 29 years) from human leukocyte antigen-
identical sibling donors. Median follow-up was 58 months in BMT recipients and 18 months in PBSCT recipients.
Neutrophil (median, Day 8 vs Day 13, p < 0.001) and platelet engraftment (median, Day 9 vs Day 17, p <
0.001) was faster in the PBSCT group than in the BMT group. Patients receiving PBSCT required less platelet
transfusion than those receiving BMT (median, 54 units vs 144 units, p < 0.001), but there was no significant
difference in red cell transfusion. At 100 days, there was no difference in the incidence of acute graft-versus-
host disease (GVHD) (42.9% vs 33.3%, p = 0.72) or grade II–IV acute GVHD (14.3% vs 5.6%, p = 0.57), and
there was no difference in the cumulative incidence of chronic GVHD (20% vs 33.3%, p = 0.67). No chronic
GVHD was noted in any relapsed patients (BMT, 5; PBSCT, 3), and no patients with chronic GVHD during
follow-up had a relapse. Relapse was the most frequent cause of death in both groups (BMT, 5/9, 55.6%; PBSCT,
3/4, 75%; p = 0.25); all relapses occurred within 1 year after transplantation. Overall survival was significantly
better in the PBSCT group (35.7% vs 77.8%, p = 0.029), but this difference was lost if only hematologic malignancies
were analyzed (30.8% vs 63.6%, p = 0.20). Our results are similar to those reported previously, with faster
neutrophil and platelet engraftment and less severe acute GVHD and extensive chronic GVHD with PBSCT.
Allogeneic PBSCT is a feasible and beneficial alternative to allogeneic BMT in adult hematologic disease.
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Hematopoietic stem cell transplantation is a widely accepted
treatment modality for many hematologic diseases,
including leukemia, myelodysplasia, lymphoma, myeloma,
and aplastic anemia. Recently, growth-factor mobilized
peripheral blood stem cell transplantation (PBSCT) has
been performed more frequently than conventional bone
marrow transplantation (BMT) [1–3]. Compared with
conventional BMT, allogeneic PBSCT is safe, with easy
collection of progenitor cells from the donor, rapid neutrophil
and platelet engraftment, and reduced transfusion
requirements and hospital stay [4–6]. The observation that
mobilized peripheral blood grafts contain approximately
10-fold more T-cells than marrow suggests a potential for
Kaohsiung J Med Sci November 2003 • Vol 19 • No 11
Y.C. Liu, C.S. Chang, T.C. Liu, et al
542
increased graft-versus-host disease (GVHD), but the results
remain conflicting [6–12]. Several prospective randomized
studies have revealed different results, i.e. some studies
revealed an increased incidence of chronic GVHD with
PBSCT while others did not, and no increase in the incidence
of acute GVHD was noted in these studies [13–17]. We
retrospectively analyzed patients who received allogeneic
BMT or PBSCT from human leukocyte antigen (HLA)-
identical sibling donors at one center, and compared the
differences in hematologic recovery, transfusion
requirements, acute and chronic GVHD, relapse and disease-
free survival, overall survival, and cause of death. We also
compared our results with those of other studies [6–17].
MATERIALS AND METHODS
Patients
We retrospectively analyzed data for patients who under-
went allogeneic hematopoietic stem cell transplantation
at Kaohsiung Medical University Hospital in southern
Taiwan between July 1993 and July 2001. Of the 61 patients
who received allogeneic hematopoietic stem cell
transplantation during this period, 29 were excluded: nine
were less than 12 years old, four used matched unrelated
donors, 15 used HLA mismatched donors (12 with one-
locus mismatch, 3 with two-loci mismatch), and one had
insufficient chart information. Thirty-two patients (BMT,
14; PBSCT, 18) included in the analysis fulfilled the following
criteria: age between 18 and 50 years, no major organ
dysfunction, and Karnofsky scores greater than 80%. The
clinical characteristics of patients are detailed in Table 1.
Donors
Donors were genotypically HLA-A-, -B-, and -DR-identical
siblings with good performance on physical examination
and normal laboratory data results. BMT donors underwent
conventional harvest with target nucleated cell yields of
2.0 × 108/kg recipient body weight. PBSCT donors were
treated with granulocyte colony-stimulating factor (G-CSF,
filgrastim) 10 µg/kg/day subcutaneously for 5 days and
leukapheresis was performed using a COBE Spectra Cell
Separator (COBE BCT Inc, Lakewood, CO, USA) until target
yields of CD34+ cells exceeded 2.5 × 106 cells/kg on two
consecutive days (Days 5 and 6). No T-cell depletion was
carried out in either group.
Preparative regimens
All patients received one of the following conditioning
Table 2. Conditioning regimens used for allogeneic stem
cell transplantation in bone marrow transplantation (BMT)
and peripheral blood stem cell transplantation (PBSCT)
recipients
Regimen BMT (n = 14) PBSCT (n = 18)
TBI/CY 3 12
TBI/VP/CY 6 5
BU/CY 5 1
TBI = total body irradiation; CY = cyclophosphamide; VP = eto-
poside; BU = busulfan.
regimens according to usual protocols (Table 2): total body
irradiation (TBI) of 1,200 rads followed by cyclophos-
phamide (CY) 60 mg/kg/day for 2 days; TBI 1,200 rads
followed by etoposide 60 mg/kg/day for 1 day and CY
50 mg/kg/day for 2 days; or busulfan 4 mg/kg/day for 4
days and CY 60 mg/kg/day for 2 days. Patients with severe
aplastic anemia received TBI 300 rads followed by CY
50 mg/kg/day for 4 days. Acyclovir prophylaxis was given
before transplantation. Ciprofloxacin, trimethoprim/
sulfamethoxazole and fluconazole were used to
decontaminate the gastrointestinal tract and provide
antipneumocystis prophylaxis. G-CSF was prescribed
at 5 µg/kg/day by subcutaneous injection from trans-
Table 1. Characteristics of patients undergoing allogeneic
bone marrow transplantation (BMT) and allogeneic
peripheral blood stem cell transplantation (PBSCT)
BMT PBSCT
(n = 14) (n = 18)
Age
Median 28 29
Range 17–47 16–46
Sex
Male 8 7
Female 6 11
Diagnosis
Acute myeloid leukemia 7 4
Acute lymphoblastic leukemia 4 3
Chronic myeloid leukemia 1 2
Severe aplastic anemia 1 6
Non-Hodgkin’s lymphoma 1 0
Multiple myeloma 0 1
Myelodysplastic syndrome 0 1
Pure red cell aplasia 0 1
Disease status
Less advanced 9 12
More advanced 5 6
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plantation Day 1 until the white blood cell count (WBC) was
more than 1,000/µL, or the absolute neutrophil count (ANC)
was more than 500/µL. Blood component therapy was
performed after gamma-irradiation (1,500 rads) according
to clinical symptoms and signs to keep the platelet count
above 20,000/µL and the hemoglobin concentration above
8.0 g/dL.
Engraftment
The day of neutrophil engraftment was defined as the first
of three consecutive days on which the patient’s ANC was
above 500/µL. The day of platelet engraftment was defined
as the first of 7 consecutive days on which the platelet count
was above 20,000/µL without the need for transfusion.
GVHD diagnosis and management
Acute GVHD was graded according to standard criteria
[18]. GVHD prophylaxis consisted of methotrexate
(15 mg/m2 on Day 1 and 10 mg/m2 on Days 3, 6, and 11)
followed by folinic acid (9 mg/m2 intravenously, q6h for
8 doses) and cyclosporine (1.5 mg/kg intravenously bid
with dose adjustment to maintain serum levels at 200–
400 µg/dL, then oral treatment). Acute and chronic GVHD
were diagnosed and managed as described previously [18].
Chronic GVHD was defined as GVHD present after Day
100 and was considered to be progressive when it appeared
as a continuation of previous acute GVHD. Chronic GVHD
was defined as de novo when there was no previous acute
GVHD, and quiescent when it reappeared after the apparent
resolution of previous acute GVHD. Biopsy confirmation of
at least one of the affected organs was required.
Statistical methods
Outcome data, such as time to engraftment of neutrophils
and platelets, transfusion requirements, development of
acute or chronic GVHD, relapse, disease-free survival,
overall survival, and causes of death, were analyzed and
compared between the two groups. Data that were not
normally distributed were analyzed using a nonparametric
test (Mann-Whitney test). The probabilities of neutrophil
and platelet recovery, acute or chronic GVHD, relapse,
disease-free survival, and overall survival were compared
using Kaplan-Meier survival analysis with log-rank analysis.
RESULTS
Hematopoietic stem cell harvest
The BMT group received a median of 2.71 × 108 (range,
2.5–3.55 × 108) nucleated cells/kg according to standard
procedure. The PBSCT group received a median of
13.35 × 108 (range, 5.48–29.8 × 108) nucleated cells/kg and
10.12 × 106 (range, 4.56–23.6 × 106) CD34+ cells/kg. G-CSF
administration was well tolerated except for mild bone
pain, which occurred in most donors.
Engraftment and transfusion requirement
All the recipients in both groups had neutrophil and platelet
engraftment, except for one patient in the BMT group who
died on Day 55 before the ANC reached 500/µL. The ANC
rose above 500/µL and the platelet count rose above
20,000/µL later in the BMT group than in the PBSCT group
(both p < 0.001) (Table 3). The requirement for platelet
transfusion was significantly less in the PBSCT group
than in the BMT group (p < 0.001), although there was
no significant difference in red cell transfusion (Table 3).
Figures 1 and 2 show the hematopoietic reconstruction.
Acute and chronic GVHD
There was no difference in the incidence of acute GVHD
between patients receiving BMT and those receiving PBSCT
(p = 0.72), nor in the cumulative incidence of grade II–IV acute
GVHD at Day 100 (p = 0.57) (Table 4). Grade III–IV acute
GVHD occurred in only one patient receiving BMT and in
none receiving PBSCT. The cumulative incidence of chronic
GVHD for those who survived more than 100 days was 20%
(2/10) in the BMT group, compared to 33.3% (6/18) in the
PBSCT group (p = 0.67). Limited chronic GVHD with skin and
mucous involvement was most common, noted in two patients
(100%) in the BMT group and four (66.7%) in the PBSCT group.
Extensive chronic GVHD was absent in BMT recipients but
occurred in two (33.3%) PBSCT recipients (p = 0.52); liver and
lung presentation was confirmed by biopsy. The most frequent
subtype of chronic GVHD was de novo GVHD (BMT, 2/2;
PBSCT, 4/6). Evidence of chronic GVHD was absent in all
relapsed patients (BMT, 5 patients; PBSCT, 3 patients), and
there was no relapse among patients with chronic GVHD
during follow-up.
Relapse, survival and causes of death
As shown in Table 5, 35.7% of BMT recipients and 16.7% of
PBSCT recipients suffered a relapse (p = 0.25). All relapse
episodes occurred within 1 year of transplantation in both
groups, and disease-free survival at 1 year was 35.7% (5/14)
in the BMT group and 77.8% (14/18) in the PBSCT group
(p = 0.16). Overall survival at 1 year was 57.1% (8/14) in the
BMT group and 77.8% (14/18) in the PBSCT group (p =
0.054), and cumulative overall survival was 35.7% (5/14)
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in the BMT group and 77.8% (14/18) in the PBSCT group
(p = 0.029) (Figure 3). Relapse was the most common cause
of death in both groups, accounting for 55.6% (5/9) of
mortality in BMT recipients and 75% (3/4) of mortality in
PBSCT recipients. Treatment-related mortality at Day 100
was noted in 28.6% (4/14) of patients in the BMT group and
none in the PBSCT group (p = 0.028). In addition to relapse,
the causes of death in the BMT group included cyto-
megalovirus (CMV) interstitial pneumonitis, no engraft-
ment, and bacterial sepsis. One patient in the PBSCT group
developed extensive chronic GVHD and died due to
Pseudomonas pneumonia with septicemia.
We further compared the survival between the two
groups, focusing on malignant hematologic diseases.
Table 3. Time to engraftment and transfusion requirements in allogeneic bone marrow transplantation (BMT) and allogeneic
peripheral blood stem cell transplantation (PBSCT) recipients
BMT (n = 14) PBSCT (n = 18) p
Time to engraftment (d)
ANC > 500/µL < 0.001
Median 13 8
Range 10–20 7–11
Platelets > 20,000/µL < 0.001
Median 17 9
Range 10–24 7–16
Transfusion requirement (units)
Red cells 0.377
Median 5 4
Range 0–22 6–12
Platelets < 0.001
Median 144 54
Range 60–546 24–144
ANC = absolute neutrophil count.
Figure 2. Probability of achieving a platelet count of more than
20,000/µL after allogeneic bone marrow transplantation (BMT) and
allogeneic peripheral blood stem cell transplantation (PBSCT) (log rank
p < 0.001). SCT = stem cell transplantation.
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Figure 1. Probability of achieving an absolute neutrophil count (ANC) of
more than 500/µL after allogeneic bone marrow transplantation (BMT)
and allogeneic peripheral blood stem cell transplantation (PBSCT) (log rank
p < 0.001). WBC = white blood cell count; SCT = stem cell transplantation.
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Table 5. Causes of death during follow-up in allogeneic
bone marrow transplantation (BMT) and allogeneic
peripheral blood stem cell transplantation (PBSCT)
recipients
BMT (n = 14) PBSCT (n = 18)     p
Number of deaths 9 4
Relapse 5 3   0.25
Bacterial sepsis 1 1
CMV pneumonitis 2 0
No engraftment 1 0
CMV = cytomegalovirus.
Table 4. Incidence of acute graft-versus-host disease
(GVHD) and chronic GVHD in allogeneic bone marrow
transplantation (BMT) and allogeneic peripheral blood
stem cell transplantation (PBSCT) recipients
BMT PBSCT p
n = 14 (%) n = 18 (%)
Acute GVHD
All 6 (42.9) 6 (33.3) 0.72
Grades II to IV 2 (14.3) 1 (5.6) 0.57
Grades III to IV 1 (7.1) 0
Chronic GVHD
All 2 6 0.67
Limited 2 4
Extensive 0 2
Figure 3. Cumulative overall survival curve in all patients receiving
allogeneic bone marrow transplantation (BMT) and allogeneic peripheral
blood stem cell transplantation (PBSCT) (log rank p = 0.029). SCT =
stem cell transplantation.
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Figure 4. Cumulative overall survival curve for allogeneic bone marrow
transplantation (BMT) and allogeneic peripheral blood stem cell
transplantation (PBSCT) in hematologic malignancies (log rank p =
 0.20). SCT = stem cell transplantation.
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Disease-free survival at 1 year was 30.8% (4/13) in the BMT
group and 63.6% (7/11) in the PBSCT group (p = 0.20).
Overall survival at 1 year was 46.2% (6/13) in the BMT
group and 72.7% (8/11) in the PBSCT group (p = 0.19), and
cumulative overall survival was 30.8% (4/13) in the BMT
group and 63.6% (7/11) in the PBSCT group (p = 0.20)
(Figure 4). Relapse was still the most common cause of
death in both groups: 38.5% (5/13) of BMT recipients and
27.3% (3/11) of PBSCT recipients (p = 0.55).
DISCUSSION
This retrospective study compared allogeneic PBSCT with
allogeneic BMT from HLA-identical siblings in adult
hematologic disease. Allogeneic PBSCT provided
significantly faster neutrophil and platelet engraftment
than allogeneic BMT and shorter stays in the laminar flow
room. In addition, the PBSCT group required significantly
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less platelet transfusion than the BMT group, although red
cell transfusion was no different. These results are generally
consistent with those of previous reports [4–6,13–17].
Interestingly, we found earlier neutrophil (median, Day 8)
and platelet engraftment (median, Day 9) with PBSCT than
other studies [4–6,13–17]. This may be due to the higher
number of CD34+ stem cells transplanted in our study and
prescription of G-CSF after transplantation. The earlier
neutrophil engraftment suggests that allogeneic PBSCT
might have benefit, compared with conventional allogeneic
BMT, in shortening neutropenic periods and in lowering
the risk of prolonged neutropenic fever, and this was also
evident in other studies [4–6,13–17].
PBSCT recipients did not have a greater incidence
of acute GVHD than BMT recipients in our study (for
all grades and grades II–IV), which is similar to previous
reports [4–6,10–17]. The possible explanations include:
G-CSF may induce T-cells to produce interleukin-4 (IL-4)
and IL-10, which down-regulate the inflammatory responses
involved in GVHD [19]; the presence of large numbers
of G-CSF-stimulated monocytes with T-cell suppressor
activity in the graft [20]; and greater numbers of dendritic
cells that induce a type 2 helper T-cell response [21].
In addition, there was a lower incidence of moderate to
severe acute GVHD (grade II or more) in both groups (BMT,
14.3%; PBSCT, 5.6%) in our study compared with other
reports.
The incidence of chronic GVHD was not significantly
increased in PBSCT recipients (33.3%) compared to BMT
recipients (20%) in our study, with a median follow-up of 58
months in BMT recipients and 18 months in PBSCT
recipients. Many retrospective studies have debated the
greater incidence of chronic GVHD in PBSCT recipients
than in BMT recipients, but no definite conclusions have
been drawn [7–12]. Several small prospective randomized
studies of chronic GVHD report conflicting results [13–16].
A large prospective randomized study by Bensinger et al
revealed no increased risk of acute or chronic GVHD with
PBSCT [17]. Some studies mention an increased risk for
developing chronic GVHD with a previous acute GVHD
episode [8,12], but no similar results were found in either
group in our study. Only two patients, in our PBSCT group,
developed limited chronic GVHD with previous grade I or
II acute GVHD episodes; six patients (2 in the BMT group
and 4 in the PBSCT group) developed de novo chronic
GVHD. There was no significant difference in the incidence
of extensive chronic GVHD in the two groups (p = 0.524),
and the incidence was less than that in other studies [7–12,
14–17]. A relationship between chronic GVHD and relapse
was noticed in previous studies, and a lower risk of relapse
due to the graft-versus-leukemia effect of allogeneic T-cells
was noted, especially in patients with chronic myelogenous
leukemia. No evidence of chronic GVHD was noted in our
relapsed patients, and no evidence of relapse was found in
patients with chronic GVHD during follow-up.
Cumulative overall survival was significantly greater
with PBSCT than BMT (35.7% vs 77.8%, p = 0.029) and there
was borderline significance in favor of PBSCT in 1-year
survival (57.1% vs 77.8%, p = 0.054). This may have been
caused by rapid engraftment and improvement in
supportive care in recent years.
There may have been statistical bias between the two
groups due to more non-hematologic malignancies in the
PBSCT group. When comparing the results in patients with
hematologic malignancies, overall survival (30.8% vs
63.6%) and 1-year survival (46.2% vs 72.7%) were better in
PBSCT than BMT recipients, although this was not
statistically significant (p = 0.20 and 0.19, respectively).
There may be a clinical benefit to PBSCT, but the
interpretation of survival benefit may be difficult due to
limited case numbers in our study; further follow-up and
analysis are necessary.
The most important cause of death in both groups was
relapse, which accounted for 55.6% of deaths in the BMT
group and 75% in the PBSCT group. Treatment-related
mortality before Day 100 accounted for 44.6% of deaths,
with two suffering from CMV interstitial pneumonitis in
the BMT group but none in the PBSCT group. One cause of
death in the PBSCT group was extensive chronic GVHD
with Pseudomonas septicemia. Other causes that have often
resulted in mortality after transplantation, such as veno-
occlusive disease or hemorrhage, were not observed in our
study.
In conclusion, G-CSF-mobilized allogeneic PBSCT
provided faster neutrophil and platelet engraftment,
decreased requirement for platelet transfusion, and
shortened laminar flow room stay and hospitalization
compared with conventional allogeneic BMT. There was no
significant increase in the incidence of acute GVHD, grade
II–IV acute GVHD, or chronic GVHD with PBSCT compared
with BMT. Higher overall survival was noted in the PBSCT
group, but there was no significant difference when only
hematologic malignancies were compared. This implied
that the number of cases was limited and that further
follow-up is necessary. Relapse constituted the most
important cause of death in both groups, and it seemed that
there was a lower risk of relapse with chronic GVHD. Our
results correlated well with those of previous studies.
Allogeneic transplantation: peripheral blood stem cell vs bone marrow
547Kaohsiung J Med Sci November 2003 • Vol 19 • No 11
REFERENCES
1. Bensinger WI, Weaver CH, Appelbaum FR, et al .
Transplantation of allogeneic peripheral blood stem cells
mobilized by recombinant human granulocyte colony-
stimulating factor. Blood 1995;85:1655–8.
2. Korbling M, Przepiorka D, Huh YO, et al. Allogeneic blood
stem cell transplantation for refractory leukemia and
lymphoma: potential advantage of blood over marrow
allografts. Blood 1995;85:1659–65.
3. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation
of allogeneic peripheral blood progenitor cells mobilized by
filgrastim (granulocyte colony-stimulating factor) Blood 1995;
85:1666–72.
4. Przepiorka D, Anderlini P, Ippoliti C, et al. Allogeneic blood
stem cell transplantation in advanced hematologic cancers.
Bone Marrow Transplant 1997;19:455–60.
5. Schmitz N, Bacigalupo A, Labopin M, et al. Transplantation of
peripheral blood progenitor cells from HLA-identical sibling
donors. Br J Haematol 1996;95:715–23.
6. Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral
blood stem cell transplantation in patients with advanced
hematologic malignancies: a retrospective comparison with
marrow transplantation. Blood 1996;88:2794–800.
7. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral
blood stem cell transplantation may be associated with a
high risk of chronic graft-versus-host disease. Blood 1997;
90:4705–9.
8. Solano C, Martinez C, Brunet S, et al. Chronic graft-versus-
host disease after allogeneic peripheral blood progenitor cell
or bone marrow transplantation from matched related donors:
a case-control study. Bone Marrow Transplant 1998;22:1129–35.
9. Brown RA, Adkins D, Khoury H, et al. Long-term follow-up
of high-risk allogeneic peripheral-blood stem cell transplant
recipients: graft-versus-host disease and transplant-related
mortality. J Clin Oncol 1999;17:806–12.
10. Champlin RE, Schmitz N, Horowitz MM, et al. Blood
stem cells compared with bone marrow as a source of
hematopoietic cells for allogeneic transplantation. Blood
2000;95:3702–9.
11. Russell JA, Larratt L, Brown C, et al. Allogeneic blood stem
cell and bone marrow transplantation for acute myelogenous
leukemia and myelodysplasia: influence of stem cell source
on outcome. Bone Marrow Transplant 1999;24:1177–83.
12. Lickliter JD, McGlave PB, DeFor TE, et al. Matched-pair
analysis of peripheral blood stem cells compared to marrow
for allogeneic transplantation. Bone Marrow Transplant 2000;
26:723–38.
13. Schmitz N, Bacigalupo A, Hasenclever D, et al. Allogeneic
bone marrow transplantation vs. filgrastim-mobilized
peripheral blood progenitor cell transplantation in patients
with early leukaemia: first results of a randomized
multicentre trial of the European Group for Blood and
Marrow Transplantation. Bone Marrow Transplant 1998;21:
995–1003.
14. Vigorito AC, Azevedo WM, Marques JF, et al. A randomized,
prospective comparison of allogeneic bone marrow and
peripheral blood progenitor cell transplantation in the
treatment of haematological malignancies. Bone Marrow
Transplant 1998;22:1145–51.
15. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-
marrow stem-cell transplantation in haematological malignant
diseases: a randomized trial. Lancet 2000;355:1231–7.
16. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of
bone marrow versus lenograstim-primed blood cell allogeneic
transplantation in patients with early-stage leukemia: a report
from the Societe Francaise de Greffe de Moelle. J Clin Oncol
2000;18:537–46.
17. Bensinger WI, Martin P, Storer B, et al. Transplantation of
bone marrow as compared with peripheral-blood cells from
HLA-identical relatives in patients with hematologic cancers.
N Engl J Med 2001;344:175–81.
18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus
Conference on Acute GVHD Grading. Bone Marrow Transplant
1995;15:825–8.
19. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL. Pretreatment of
donor mice with granulocyte colony-stimulating factor
polarizes donor T lymphocytes toward type-2 cytokine
production and reduces severity of experimental graft-versus-
host disease. Blood 1995;86:4422–9.
20. Mielcarek M, Roecklein BA, Torok-Storb B. CD14+ cells in
granulocyte colony-stimulating factor (G-CSF) mobilized
peripheral blood mononuclear cells induce secretion of
interleukin-6 and G-CSF by marrow stroma. Blood 1996;87:
574–80.
21. Arpinati M, Green CL, Heimfeld S, et al. Granulocyte-colony
stimulating factor mobilizes T helper 2-inducing dendritic
cells. Blood 2000;95:2484–90.
